Scinai Immunotherapeutics (SCNI) Assets (2015 - 2026)

Scinai Immunotherapeutics has disclosed Assets across 12 years of filings, most recently posting $17.2 million for Q2 2026.

• In Q2 2026, Assets rose 45.06% year-over-year to $17.2 million; the TTM figure through Jun 2026 stood at $17.2 million (up 45.06% YoY), while the FY2025 annual figure was $11.6 million, down 13.55% from the prior year.
• Assets came in at $17.2 million for Q2 2026 at Scinai Immunotherapeutics, down from $17.6 million in the prior quarter.
• In the past five years, Assets ranged from a high of $27.1 million in Q4 2022 to a low of $11.6 million in Q4 2025.
• Average Assets over 5 years is $17.8 million, with a median of $17.5 million recorded in 2023.
• Year-over-year, Assets plunged 35.45% in 2023 and soared 45.06% in 2026.
• Over 5 years, Assets stood at $27.1 million in 2022, then slumped by 35.45% to $17.5 million in 2023, then dropped by 23.03% to $13.4 million in 2024, then decreased by 13.55% to $11.6 million in 2025, then surged by 47.73% to $17.2 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $17.2 million in Q2 2026, $17.6 million in Q1 2026, and $11.6 million in Q4 2025.